explore -WSS

explore

author：comprehensive 2025-09-14 18:33:08 - browse：93727

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Crinetics acromegaly drug succeeds in late

entertainment

WSS

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

As AI in medicine takes off, can 'human in the loop' prevent harm?

RaDonda Vaught links Vanderbilt hospital issues to patient death

Medicaid rebukes states for mistakenly disenrolling children

Illumina names Agilent executive as new CEO

First U.S. drug developed to treat liver disease MASH is approved

hotspot

explore

focus

Medicare proposal to cover medical devices draws a mixed reaction

As AI in medicine takes off, can 'human in the loop' prevent harm?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Trump surgeon general acknowledges mistakes during Covid

Continuity nursing helped my family in our darkest PICU moments

Trump surgeon general acknowledges mistakes during Covid

In Memoriam: Notable people who died in 2023

Amazon on where the company's health care bets are headed next

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA advisers back CAR

focus

RaDonda Vaught links Vanderbilt hospital issues to patient death

Why Novartis is changing the name of its research labs

Stem cell treatment guidelines are released by FDA

The (many) problems with a new study criticizing cancer screening

Readout Newsletter: Bristol, Sangamo, Gilead, and more

How to fix cancer clinical trials' diversity problem

entertainment

focus

explore

hotspot